Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide.

Key facts

Study ID

NCT00083577

Run by

University of Arkansas

People needed

250

Starts

1998-02-01

Expected to finish

2005-05-01

Last updated by the study team

2010-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients must have a confirmed diagnosis of previously treated, active multiple myeloma
• Myeloma protein should be evident from which to evaluate response
• Must be 18 years of age or older. Women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
• Patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug
• Patients must have a total white blood cell count of 2,000 K/microliters. Patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma
• Patients must have adequate liver function as demonstrated by a direct bilirubin of < or = 2.0 mg/dL.

You may not qualify if…

• Patients must not have an active infection requiring parenteral antibiotics
• No other concurrent therapy for myeloma is permitted while on Thalidomide

Where it is running

• University of Arkansas for Medical Sciences/MIRT — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.